Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Dysport for Pediatric Limb Spasticity

Ipsen news release; 2016 Aug 1

The FDA has approved an abobotulinumtoxinA (Dysport) injection for treating children aged ≥2 years who have pediatric lower limb spasticity.

Indications: Dysport, the first and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity, is an injectable form of botulinum toxin type A (BoNT-A), which is isolated and purified from Clostridium bacteria producing BoNT-A. It is supplied as a lyophilized powder.

Dosage/administration: Recommended total Dysport dose per treatment session is 10 to 15 units/kg per limb. Total dose per treatment session must not exceed 15 units/kg for unilateral lower limb injections, 30 units/kg for bilateral injections, or 1,000 units, whichever is lower. Re-treatment, based on return of clinical symptoms, should not occur in intervals of less than 12 weeks.

Adverse reactions: Most common adverse reactions (≥10% in any group and greater than placebo) in pediatric patients with lower limb spasticity for Dysport 10 units/kg, 15 units/kg, 20 units/kg, or 30 units/kg, were upper respiratory tract infection, nasopharyngitis, influenza, pharyngitis, cough, and pyrexia.


Ipsen Pharmaceuticals, Inc. announces FDA approval of Dysport (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged 2 and older. [news release]. Basking Ridge, NJ: Ipsen; Aug. 1, 2016: Accessed Aug. 1, 2016.